Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Kidney Transplantation

  Free Subscription


Articles published in Br J Clin Pharmacol

Retrieve available abstracts of 17 articles:
HTML format
Text format



Single Articles


    July 2018
  1. MD DOM ZI, Coller JK, Carroll RP, Tuke J, et al
    Mycophenolic Acid Concentrations in Peripheral Blood Mononuclear Cells are Associated with the Incidence of Rejection in Renal Transplant Recipients.
    Br J Clin Pharmacol. 2018 Jul 2. doi: 10.1111/bcp.13704.
    PubMed     Text format     Abstract available


    April 2018
  2. LIN XB, Li ZW, Yan M, Zhang BK, et al
    Population Pharmacokinetics of Voriconazole and CYP2C19 Polymorphisms for Optimizing Dosing Regimens in Renal Transplant Recipients.
    Br J Clin Pharmacol. 2018 Apr 1. doi: 10.1111/bcp.13595.
    PubMed     Text format     Abstract available


    January 2018
  3. VAN SLOTEN TT, de Klaver PAG, van den Wall Bake AWL
    Co-administration of cyclosporine and ticagrelor may lead to a higher exposure to cyclosporine: a case report of a 49-year-old man.
    Br J Clin Pharmacol. 2018;84:208-210.
    PubMed     Text format     Abstract available


    September 2017
  4. MAO JJ, Jiao Z, Yun HY, Zhao CY, et al
    External Evaluation of Population Pharmacokinetic Models for Cyclosporine in Adult Renal Transplant Recipients.
    Br J Clin Pharmacol. 2017 Sep 11. doi: 10.1111/bcp.13431.
    PubMed     Text format     Abstract available


  5. MILLAN O, Budde K, Sommerer C, Aliart I, et al
    Urinary miR-155-5p and CXCL10 as prognostic and predictive biomarkers of rejection, graft outcome and treatment response in kidney transplantation.
    Br J Clin Pharmacol. 2017 Sep 7. doi: 10.1111/bcp.13399.
    PubMed     Text format     Abstract available


    July 2017
  6. BREMER S, Vethe NT, Skauby M, Kasbo M, et al
    NFAT-regulated cytokine gene expression during tacrolimus therapy early after renal transplantation.
    Br J Clin Pharmacol. 2017 Jul 7. doi: 10.1111/bcp.13367.
    PubMed     Text format     Abstract available


    June 2017
  7. VANHOVE T, Hasan M, Annaert P, Oswald S, et al
    Pretransplant 4beta-hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation.
    Br J Clin Pharmacol. 2017 Jun 11. doi: 10.1111/bcp.13343.
    PubMed     Text format     Abstract available


  8. STORSET E, Hole K, Midtvedt K, Bergan S, et al
    Response to: 'Response to: Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance'.
    Br J Clin Pharmacol. 2017;83:1357-1358.
    PubMed     Text format    


  9. VANHOVE T, Annaert P, Kuypers DRJ
    Response to: 'Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance'.
    Br J Clin Pharmacol. 2017;83:1353-1356.
    PubMed     Text format    


  10. STORSET E, Hole K, Midtvedt K, Bergan S, et al
    Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance.
    Br J Clin Pharmacol. 2017;83:1350-1352.
    PubMed     Text format    


    April 2017
  11. KNOPS N, Herman J, van Dyck M, Ramazani Y, et al
    Tacrolimus dose requirements in paediatric renal allograft recipients are characterized by a biphasic course determined by age and bone maturation.
    Br J Clin Pharmacol. 2017;83:863-874.
    PubMed     Text format     Abstract available


    March 2017
  12. RIVOLI L, Vliegenthart AD, de Potter CM, van Bragt JJ, et al
    The effect of renal dysfunction and haemodialysis on circulating liver specific miR-122.
    Br J Clin Pharmacol. 2017;83:584-592.
    PubMed     Text format     Abstract available


    February 2017
  13. STORSET E, Hole K, Midtvedt K, Bergan S, et al
    THE CYP3A BIOMARKER 4beta-HYDROXYCHOLESTEROL DOES NOT IMPROVE TACROLIMUS DOSE PREDICTIONS EARLY AFTER KIDNEY TRANSPLANTATION.
    Br J Clin Pharmacol. 2017 Feb 1. doi: 10.1111/bcp.13248.
    PubMed     Text format     Abstract available


    October 2016
  14. TANG JT, de Winter BC, Hesselink DA, Sombogaard F, et al
    THE PHARMACOKINETICS AND PHARMACODYNAMICS OF MYCOPHENOLATE MOFETIL IN YOUNGER AND ELDERLY RENAL TRANSPLANT RECIPIENTS.
    Br J Clin Pharmacol. 2016 Oct 18. doi: 10.1111/bcp.13154.
    PubMed     Text format     Abstract available


    July 2016
  15. MOES DJ, Press RR, Ackaert O, Ploeger BA, et al
    Exploring genetic and non-genetic risk factors for delayed graft function, acute and subclinical rejection in renal transplant recipients.
    Br J Clin Pharmacol. 2016;82:227-37.
    PubMed     Text format     Abstract available


    December 2015
  16. SUZUKI Y, Fujioka T, Sato F, Matsumoto K, et al
    CYP3A5 polymorphism affects the increase in CYP3A activity after living kidney transplantation in patients with end stage renal disease.
    Br J Clin Pharmacol. 2015;80:1421-8.
    PubMed     Text format     Abstract available


    November 2015
  17. ZHAO CY, Jiao Z, Mao JJ, Qiu XY, et al
    External Evaluation of Published Population Pharmacokinetic Models of Tacrolimus in Adult Renal Transplant Recipients.
    Br J Clin Pharmacol. 2015 Nov 17. doi: 10.1111/bcp.12830.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Kidney Transplantation is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: